Mesalazine

Evidence Level: L5

Predicted Indications: 6

Mesalazine

Pharmacist Assessment Report

Mesalazine: Congenital hypotrichosis with juvenile macular dystrophy

One-Sentence Summary

Mesalazine (5-aminosalicylic acid) was originally used to treat ulcerative colitis and other inflammatory bowel conditions. The TxGNN model predicts it may be effective for congenital hypotrichosis with juvenile macular dystrophy, but no clinical trials and no publications support this prediction, so it rests on a computational score alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Congenital hypotrichosis with juvenile macular dystrophy
TxGNN Prediction Score	0.9965
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, mesalazine is an aminosalicylate anti-inflammatory agent. Its efficacy in ulcerative colitis is established, and its activity is generally attributed to reduced prostaglandin and leukotriene synthesis, PPAR-gamma activation and NF-kB modulation.

For this predicted indication, no credible mechanistic link was identified. Congenital hypotrichosis with juvenile macular dystrophy is an ultra-rare genetic disorder caused by CDH3 (cadherin-3) mutations that affect hair follicle and retinal development. Mesalazine’s anti-inflammatory activity has no plausible connection to this structural defect.

The high TxGNN score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. It is not backed by any trial or publication. It should be treated as a hypothesis only.

Other Predicted Indications (for context)

Rank	Predicted Indication	Score	Evidence Level	Assessment
2	Osteoarthritis	0.9963	L5	Theoretical anti-inflammatory rationale, but poor systemic absorption limits joint exposure. The only publication is a computational target-identification study, not clinical evidence.
3	Rheumatoid arthritis	0.9957	L4	Indirect rationale via sulfasalazine, which is metabolised to mesalazine. The antirheumatic effect is mainly attributed to sulfapyridine or the intact parent compound, and mesalazine alone has not shown comparable efficacy.
4	Seborrheic keratosis	0.9950	L5	No credible mechanistic link.
6	Vulvar inverted follicular keratosis	0.9933	L5	No plausible mechanistic link.
7	Pseudoachondroplasia	0.9919	L5	COMP-mutation skeletal dysplasia, with no link to mesalazine’s mechanism.

Of the seven predictions, rheumatoid arthritis has the most (though still indirect) support.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for the top-ranked prediction.

India Market Information

All 20 registrations are valid single-ingredient products. The licence records contain no approved indication text. The five main authorizations are listed below.

Authorization Number	Product Name	Dosage Form	Approved Indication
184427	Rowasa 1gm Pellets (Abbott)	Packet of 1 gm pellets	Not stated in records
133634	Mesacol Tablet DR (Sun Pharmaceutical)	Strip of 15 delayed-release tablets	Not stated in records
174418	Pentasa 1gm Enema (Ferring)	Bottle of 100 ml enema	Not stated in records
174017	Pentasa 2gm Prolonged Release Granules (Ferring)	Sachet of 2 gm granules	Not stated in records
133780	Mesacol Suppository (Sun Pharmaceutical)	Strip of 5 suppositories	Not stated in records

Available forms include oral tablets, granules and pellets, enemas and suppositories.

Safety Considerations

Kidney and liver conditions: The knowledge graph links mesalazine to contraindication or caution in kidney disease, interstitial nephritis, lipoid nephrosis, pyoureter, liver disease and gallbladder disease.
Blood disorders: Neutropenia, agranulocytosis, anaemia and macrocytic anaemia are listed. These are knowledge-graph relationships, not label text.
Pyloric stenosis: Also listed in the knowledge graph.
Drug interactions: 291 interactions were identified. Major ones include cidofovir and human botulinum neurotoxin A/B immune globulin. Moderate ones include NSAIDs (ketorolac, ibuprofen, celecoxib, bromfenac), azathioprine, aminoglycosides (amikacin), amphotericin B formulations, acyclovir, cisplatin, capreomycin and sulfonylureas (chlorpropamide, acetohexamide). Many of these relate to additive kidney toxicity.
Reported adverse reactions in the literature: Published case reports describe 5-ASA-induced colitis and DRESS syndrome with acute renal failure after mesalazine exposure.

Package insert warnings and contraindications were not available for this report. Please refer to the package insert for authoritative safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction rests only on a score from the TxGNN model (deep learning), which may reflect similarities the model learned between related diseases, not biological evidence. It has no clinical trials or publications and no plausible mechanistic link to mesalazine’s anti-inflammatory action. The evidence level is L5.

To proceed, the following is needed:

Package insert warnings and contraindications from the India regulatory source (currently a blocking gap for safety screening)
Mechanism of action data from DrugBank
For the top prediction, a mechanistic rationale linking mesalazine to CDH3-related pathology, plus any preclinical evidence
If a more actionable direction is wanted, re-prioritise rheumatoid arthritis (L4) and review direct evidence for mesalazine, as opposed to sulfasalazine, in that condition
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.